100 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
drugs and treatments. Women's Health: Providing differentiated genetic insights for women of all ancestries, assessing cancer risk, and offering … -generation RNA expression test used to determine which women with breast cancer may benefit from chemotherapy. EndoPredict predicts the likelihood
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
16 Jan 24
Results of Operations and Financial Condition
9:00am
third-party global consulting firm and internal Company estimates 6 A leader in health and wellness with differentiated genetic insights for women … ~332M TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT ~50M* TOTAL NUMBER OF WOMEN WHO QUALIFY FOR HCT ~25M WOMEN WHO QUALIFY FOR HCT AND ARE ACTIVELY
424B5
kih tykduz7gm3vj
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
ofxifak
8 Nov 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
olgti erl
6 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
uy1uoc8hr76
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
ybzsmh4e0 a40
3 May 23
Results of Operations and Financial Condition
4:06pm
ARS
xe5re7d5sqhw
12 Apr 23
Annual report to shareholders
4:10pm
8-K
EX-99.1
ma2cai4
1 Nov 22
Myriad Genetics Reports Third Quarter Financial Results
9:03am
8-K
EX-99.1
i8le4rwy yxnxac2t1
4 Aug 22
Myriad Genetics Reports Second Quarter Financial Results
7:06am
8-K
EX-99.1
dxcpjxnbvbjh8
5 May 22
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
7:05am